Skip to main content
Mankind Pharma Limited logo

Mankind Pharma Limited — Investor Relations & Filings

Ticker · MANKIND ISIN · INE634S01028 LEI · 33580067G8AZ7S8NYA02 BSE.NS Manufacturing
Open in API
Filings indexed 397 across all filing types
Latest filing 2024-11-06 Regulatory Filings
Country IN India
Listing BSE.NS MANKIND

About Mankind Pharma Limited

https://www.mankindpharma.com/

Mankind Pharma Limited focuses on the development, manufacturing, and marketing of a broad spectrum of pharmaceutical formulations and consumer healthcare products. The company’s portfolio spans various therapeutic areas, including anti-infectives, cardiovascular, gastrointestinal, dermatology, and respiratory health. It maintains a significant presence in the over-the-counter segment with brands such as Manforce, Prega News, and Gas-O-Fast. The organization operates a robust research and development infrastructure dedicated to creating affordable and accessible medicinal solutions. Its operational model leverages an extensive distribution network to ensure product availability across diverse geographic regions, prioritizing high-quality healthcare delivery and patient-centric innovation.

Recent filings

Filing Released Lang Actions
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a short notice informing stock exchanges about the company's participation in an upcoming Annual Investor Conference. It explicitly states that no unpublished price sensitive information will be shared and is intended for regulatory compliance under SEBI listing obligations. There are no financial statements, detailed financial data, or report attachments. The document is an announcement of participation in an investor event, not a financial report or detailed presentation. Given the content and length (1299 characters), it fits best as a Regulatory Filing (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2024-11-06 English
Credit Rating
Capital/Financing Update Classification · 95% confidence The document is a formal letter addressed to stock exchanges informing about the reaffirmation of credit ratings by CRISIL Ratings Limited for various financial instruments of the company. It references SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, indicating a regulatory compliance announcement. The content is an update on credit rating status, not a full financial report, audit, or earnings release. The document length is short (1489 characters) and it serves as an official notification rather than a detailed report. Therefore, it fits best under Capital/Financing Update (CAP) as it relates to credit rating information which impacts the company's financing and capital structure.
2024-11-06 English
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript Classification · 95% confidence The document is a short communication dated November 5, 2024, addressed to stock exchanges and shareholders. It announces the availability of the audio recording of an investor conference call for Q2 & H1 FY25. The text references the SEBI regulations and provides a link to the recording. There is no detailed transcript or financial data included, only a notification about the call recording. According to the classification rules, announcements about conference call recordings or invitations are classified as Call Transcript (CT) if the full transcript is provided, but here only the audio recording availability is announced, not the transcript itself. However, since the document is about the investor conference call and its recording, the closest and most appropriate classification is Call Transcript (CT), as it relates directly to the earnings call content. Confidence is high because the document explicitly mentions the investor conference call and the Q2 & H1 FY25 period.
2024-11-05 English
Resignation
Regulatory Filings
2024-11-05 English
Press Release
Earnings Release Classification · 95% confidence The document is a press release dated November 5, 2024, announcing the financial results for the second quarter and six months ended September 30, 2024 (Q2FY25 and H1 FY25). It includes detailed financial performance metrics such as revenue, EBITDA, PAT, segmental revenue, and EPS. The document also mentions an upcoming earnings conference call. The content is typical of an Earnings Release (ER), which is an initial announcement of quarterly financial results with key highlights. The document is about 11,389 characters long, which is consistent with a detailed press release but not a full interim or annual report. There is no indication that this is a full interim report (IR) with comprehensive financial statements or management discussion, nor is it an Annual Report (10-K). It is not a regulatory filing or certification, nor a presentation or call transcript. Therefore, the best classification is Earnings Release (ER). Q2 2025
2024-11-05 English
Investor Presentation
Regulatory Filings
2024-11-05 English

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.